SCYNEXIS (SCYX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	16.60 mm	16.60 mm	16.60 mm	16.60 mm	16.60 mm	16.60 mm
Cash burn (monthly)	4.23 mm	1.50 mm	2.68 mm	3.53 mm	3.30 mm	2.00 mm
Cash used (since last report)	15.52 mm	5.51 mm	9.86 mm	12.95 mm	12.13 mm	7.35 mm
Cash remaining	1.08 mm	11.09 mm	6.74 mm	3.64 mm	4.47 mm	9.25 mm
Runway (months of cash)	0.3	7.4	2.5	1.0	1.4	4.6

Beta Read what these cash burn values mean

Financial data from SCYNEXIS earnings reports.

Institutional ownership, Q4 2024

SCYX institutional ownership history Ownership history

38.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	52	40	+30.0%
Opened positions	17	37	-54.1%
Closed positions	5	2	+150.0%
Increased positions	15	0	NEW
Reduced positions	6	0	NEW

13F shares	Current	Prev Q	Change
Total value	14.04 bn	13.25 bn	+6.0%
Total shares	15.00 mm	12.35 mm	+21.4%
Total puts	0.00	0.00
Total calls	30.40 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
FHI Federated Hermes	2.90 mm	$3.50 bn	-19.5%
Kingdon Capital Management, L.L.C.	2.24 mm	$2.71 bn	NEW
Vanguard	1.66 mm	$2.01 bn	-1.5%
Flynn James E	1.50 mm	$0.00	0.0%
Avidity Partners Management	1.23 mm	$1.49 bn	NEW
Hirschman Orin	1.16 mm	$2.32 mm	0.0%
AMH Equity	626.05 k	$757.52 mm	+4.3%
Acadian Asset Management	467.27 k	$564.00 k	-13.6%
BlackRock	426.21 k	$515.72 mm	+0.1%
Bridgeway Capital Management	423.49 k	$512.42 mm	+0.2%

Largest transactions	Shares	Bought/sold	Change
Kingdon Capital Management, L.L.C.	2.24 mm	+2.24 mm	NEW
Avidity Partners Management	1.23 mm	+1.23 mm	NEW
FHI Federated Hermes	2.90 mm	-700.00 k	-19.5%
D.a. Davidson & Co.	0.00	-527.70 k	EXIT
Citadel Advisors	97.93 k	+97.93 k	NEW
Acadian Asset Management	467.27 k	-73.42 k	-13.6%
UBS UBS	84.57 k	+69.56 k	+463.5%
NTRS Northern Trust	153.52 k	+52.47 k	+51.9%
Squarepoint Ops	43.86 k	+43.86 k	NEW
Engineers Gate Manager	42.23 k	+42.23 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SCYX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Apr 25	Gonzalez David Angulo	Common Stock	Grant	Acquire A	No	No	0.84	23,000	19.32 k	816,598
20 Mar 25	Gonzalez David Angulo	Common Stock	Grant	Acquire A	No	No	1.05	13,800	14.49 k	793,598
19 Mar 25	Gonzalez David Angulo	Common Stock	Grant	Acquire A	No	No	1.07	5,000	5.35 k	779,798
23 Jan 25	Gonzalez David Angulo	Common Stock	Grant	Acquire A	No	No	0	262,927	0.00	770,798
23 Jan 25	Gonzalez David Angulo	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.08	394,391	425.94 k	394,391
23 Jan 25	ivor Macleod	Common Stock	Grant	Acquire A	No	No	0	92,511	0.00	260,696
23 Jan 25	ivor Macleod	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.08	138,767	149.87 k	138,767
23 Jan 25	Scott Sukenick	Common Stock	Grant	Acquire A	No	No	0	92,511	0.00	436,706
23 Jan 25	Scott Sukenick	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.08	138,767	149.87 k	138,767

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

SCYNEXIS To Present Preclinical Data On Second Generation IV/Oral Fungerp SCY-247 At The European Society Of Clinical Microbiology And Infectious Diseases

8 Apr 25

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy

Press releases

From Benzinga Pro

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

12 Mar 25

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European